Analyst Price Targets — ZNTL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 10, 2026 10:56 am | — | Guggenheim | $10.00 | $6.14 | TheFly | Zentalis price target raised to $10 from $6 at Guggenheim |
| November 11, 2025 9:50 am | Andrew Berens | Leerink Partners | $2.00 | $1.32 | StreetInsider | Zentalis Pharmaceuticals (ZNTL) PT Lowered to $2 at Leerink Partners |
| June 18, 2024 2:17 pm | Akash Tewari | Jefferies | $6.00 | $4.31 | TheFly | Zentalis downgraded to Hold from Buy at Jefferies |
| June 18, 2024 1:32 pm | Matthew Harrison | Morgan Stanley | $8.00 | $4.14 | StreetInsider | Morgan Stanley Downgrades Zentalis Pharmaceuticals (ZNTL) to Equalweight |
| June 18, 2024 11:46 am | Bradley Canino | Stifel Nicolaus | $10.00 | $5.39 | TheFly | Zentalis price target lowered to $10 from $32 at Stifel |
| June 18, 2024 10:45 am | Robert Driscoll | Wedbush | $4.00 | $5.70 | TheFly | Wedbush downgrades Zentalis to Underperform on unclear azeno path forward |
| May 7, 2024 4:31 pm | Bradley Canino | Stifel Nicolaus | $32.00 | $12.43 | StreetInsider | Zentalis Pharmaceuticals (ZNTL) PT Lowered to $32 at Stifel |
| November 14, 2022 9:32 am | — | Wedbush | $32.00 | $22.56 | Benzinga | Wedbush Maintains Outperform on Zentalis Pharmaceuticals, Lowers Price Target to $32 |
| November 11, 2022 9:12 am | — | Morgan Stanley | $55.00 | $20.90 | Benzinga | Morgan Stanley Maintains Overweight on Zentalis Pharmaceuticals, Lowers Price Target to $55 |
| November 11, 2022 8:46 am | — | Guggenheim | $28.00 | $21.35 | Benzinga | Guggenheim Maintains Buy on Zentalis Pharmaceuticals, Lowers Price Target to $28 |
Latest News for ZNTL
SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced data from two posters being presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking…
Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) shares are surging Friday after a Guggenheim analyst raised the price target from $6 to $10.
Planned interim analysis from DENALI Part 2a showed a clearly differentiated response rate at 400mg QD 5:2 over 300mg QD 5:2 and comparable safety profiles between the two dose groups Azenosertib therapeutic profile supports Phase 2 DENALI and Phase 3 ASPENOVA advancement as well as initiation of pre-commercial activities DENALI Part 2 topline readout expected by year end 2026 SAN DIEGO, April 09, 2026 (GLOBE…
SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on April 1, 2026, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to…
On track for DENALI Part 2a dose confirmation in 1H 2026 DENALI Part 2 trial topline readout expected by year end 2026; potential to support accelerated approval On track to initiate the ASPENOVA Phase 3, randomized, confirmatory trial in 1H 2026 Expanding azenosertib potential in ovarian cancer with the ongoing MUIR Part 2 trial evaluating the combination of azenosertib and bevacizumab as maintenance therapy $245.9…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ZNTL.
U.S. House Trading
No House trades found for ZNTL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.